ABSTRACT
Background@#Cost-effectivenessstudiesareimportant for chronic diseases such as psoriasis, which may cause significant financial burden and negatively affect the patient's quality of life.@*Objectives@#This study evaluated which among the treatment options, namely topicals phototherapy (TP), topicals + systemic (TS), and topicals + biologics (TB), is the most cost-effective for the management of moderate to severe psoriasis at the Rizal Medical Center's Psoriasis Center@*Methods@#A total of 65 moderate to severe psoriasis patients seen at the Rizal Medical Center's Psoriasis Center in 2021 were included in this retrospective cross-sectional study. Chart review was conducted to account all direct costs of treatment. The effectiveness in relation to the overall cost was assessed using the psoriasis area severity index (PASI) and the dermatological life quality index (DLQI).@*Results@#Our study showed that TS is the most cost-effective treatment for moderate to severe psoriasis with the lowest cost per PASI75 and DLQI<5 improvement valued at Php335.36, followed by TP valued at Php 762.87, and lastly by TB at Php 19,058.03. Despite TB incurring the highest cost, all patients in this treatment group showed the highest mean difference of PASI and DLQI.@*Conclusions@#Our findings suggest that topical with systemic medication is the most cost-effective treatment for moderate to severe psoriasis
Subject(s)
Psoriasis , Cost-Effectiveness AnalysisABSTRACT
Marco teórico: la asociación entre psoriasis y daño orgánico y psicológico está ampliamente descrita. Existen pocos estudios que la relacionen con la salud sexual. Objetivo: Establecer la relación entre cambios en la severidad de la psoriasis y la salud sexual en un grupo de pacientes chilenos. Pacientes y métodos: 47 pacientes chilenos portadores de psoriasis vulgar. Se realizó una encuesta epidemiológica, PASI y una entrevista llamada CSFQ-14, que evalúa la respuesta sexual. A los 3 meses de tratamiento, fueron reevaluados. Resultados: El PASI promedio disminuyó al tercer mes (p < 0.01). En los promedios de CSFQ-14, no hubo variación del total de la muestra (p > 0.05), pero al comparar sexos, tanto en día 1 como en día 3 fueron mayores en hombres (p < 0.01). Conclusión: En un primer estudio en población chilena, no se encontró relación entre cambios en la psoriasis y la salud sexual.
Background: The association between psoriasis and organic and mental damage is widely described. Few studies link this condition to sexual health. Objective: To establish the relationship between changes in the severity of psoriasis and sexual health in a group of Chilean patients. Patients and Methods:47 Chilean patients, submitted to an epidemiological survey, PASI, and an interview called CSFQ-14, which evaluates sexual response. After 3 months of treatment, they were re-assessed. Results: A decrease in average PASI was found after 3 months(p < 0.01). There was no change in the average CSFQ-14 scores of the total sample in the third month (p > 0.05). However, when comparing between sexes, either on day 1 or month 3, CSFQ-14 scores were higher in men (p < 0.01). Conclusion: In a first study using Chilean population, no relationship was found between changes in psoriasis and sexual health.
Subject(s)
Humans , Male , Adult , Female , Middle Aged , Psoriasis/psychology , Psoriasis/therapy , Quality of Life , Sexual Health , Sex Factors , Surveys and QuestionnairesABSTRACT
La psoriasis es una enfermedad de filiación inmunológica, frecuente a nivel mundial. En población europea y en EE.UU. reporta una prevalencia del 0,6 al 4%. No hay reportes en Uruguay. La forma clásica de presentación es la vulgar en placas. Si bien en la mayoría de los casos es paucisintomática y las terapias tópicas permiten su control (psoriasis leve), en una proporción importante de casos es capaz de afectar severamente la calidad de vida al generalizarse o asociar afectación de otros órganos, o en casos extremos inclusive llevar a la muerte. El objetivo principal de este artículo es brindar recomendaciones unificadas sobre el tratamiento de la psoriasis vulgar en placas moderada y severa. En esta parte se discuten tratamientos sistémicos ‘convencionales’, priorizando la fototerapia, metotrexato, ciclosporina A y retinoides. Aquí no se incluirán las terapias dirigidas contra blancos moleculares (llamadas ‘terapias biológicas’) que ya constituyen alternativas convencionales en los países desarrollados.
Psoriasis is a common worldwide disease and is considered of immune affiliation. In Europe and the U.S. population reported a prevalence of 0.6 to 4%. There are no reports of Uruguay prevalence. The classic presentation is vulgar plates. Although in most cases the disease is paucisymptomatic and topical therapies allows control (mild psoriasis), in a significant proportion can severely affect quality of life associated with generalized psoriasis or involvement of other organs. Even lead to death. The main objective of this article is to provide unified guidelines on the treatment of chronic plaque psoriasis with moderate to severe presentation. This part discusses systemic ‘conventional’ treatments, giving priority to phototherapy, methotrexate, cyclosporin A and retinoids. The so called ‘Biologic Therapies’ wich are already conventional alternatives in developed countries, will be the subject of Part II of these recommendations.